Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Oct 3:18:1053-1057.
doi: 10.12659/ajcr.905759.

Systemic Mastocytosis in Association with Small Lymphocytic Lymphoma

Affiliations
Case Reports

Systemic Mastocytosis in Association with Small Lymphocytic Lymphoma

Muhammad F Iqbal et al. Am J Case Rep. .

Abstract

BACKGROUND Systemic mastocytosis with an associated hematologic non-mast cell lineage disease is a rare entity, and the majority of systemic mastocytosis cases are associated with myeloid neoplasm. Lymphoproliferative disorders are less commonly associated with systemic mastocytosis and a few cases of systemic mastocytosis associated with chronic lymphocytic leukemia have been described in the literature. CASE REPORT We present a case of indolent systemic mastocytosis associated with small lymphocytic lymphoma. The bone marrow biopsy demonstrated mast cells in the form of clusters and perivascular distribution on immunohistochemistry for tryptase, CD2, and CD25 markers. In addition, 30% involvement by small lymphocytic lymphoma was discovered in the form of interstitial lymphoid aggregates composed of small lymphocytes. Flow cytometry showed B-cells positively stained for CD19, CD20, CD5, CD23, and kappa light chains, and the CD38 expression was <5%. CONCLUSIONS In systemic mastocytosis with an associated hematologic non-mast cell lineage disease, the combination of systemic mastocytosis associated with small lymphocytic lymphoma is rare and the management strategy follows the principle of treating the two entities individually as if they are not related. Clinical surveillance is indicated for indolent systemic mastocytosis and low-risk small lymphocytic lymphoma to monitor for disease progression.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Conflict of interest

None.

Figures

Figure 1.
Figure 1.
(A) Bone marrow crush preparation shows mast cell with surrounding maturing granulocytes (Wright stain ×1,000). (B) A degranulating mast cell as indicated by an arrow.
Figure 2.
Figure 2.
Immunohistochemical stains show that the lymphoid infiltrate is composed of mainly B-cells (CD20+ A). There is increased interstitial population of mast cells with perivascular accentuation as highlighted by the tryptase stain (B).
Figure 3.
Figure 3.
(A, B) Hematoxylin and eosin sections of clot show bone marrow with several intermediate sized interstitial lymphoid aggregates composed of small lymphocytes. (200×, 500×).

Similar articles

Cited by

References

    1. Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112(4):946–56. - PMC - PubMed
    1. Golkar L, Bernhard JD. Mastocytosis. Lancet. 1997;349(9062):1379–85. - PubMed
    1. Horny HP, Sotlar K, Valent P. Mastocytosis: State of the art. Pathobiology. 2007;74(2):121–32. - PubMed
    1. Austen KF. Systemic mastocytosis. N Engl J Med. 1992;326(9):639–40. - PubMed
    1. Castells MC. Mastocytosis: Classification, diagnosis, and clinical presentation. Allergy Asthma Proc. 2004;25(1):33–36. - PubMed

Publication types